Table 4.
Treatment, complications and outcomes of confirmed cases of Rickettsia africae infection
| Total cases n=108 | |
|---|---|
|
| |
| Antibiotic therapy * | |
| Monotherapy | 83/90 (92.2%) |
| Doxycycline | 77/83 (92.8%) |
| Ciprofloxacin | 2/83 (2.4%) |
| Minocycline | 1/83 (1.2%) |
| Amoxicillin | 1/83 (1.2%) |
| Pristinamycin | 1/83 (1.2%) |
| Rifampicin | 1/83 (1.2%) |
| Combined therapy | 7/90 (7.8%) |
| Doxycycline + Ciprofloxacin | 2/7 (28.6%) |
| Doxycycline + Amoxicillin | 1/7 (14.3%) |
| Doxycycline + Amoxicillin + Gentamicin | 1/7 (14.3%) |
| Doxycycline + Amoxicillin + Oxacillin | 1/7 (14.3%) |
| Minocycline + Ciprofloxacin | 1/7 (14.3%) |
| Cotrimoxazol + Erythromycin | 1/7 (14.3%) |
|
| |
| Complications | 4/108 (3.7%) |
| Purpuric cellulitis | 2/108 (1.9%) |
| Myocarditis | 1/108 (0.9%) |
| Neurological syndrome | 1/108 (0.9%) |
|
| |
| Need for hospitalization † | |
| Yes | 9/72 (12.5%) |
| No | 63/72 (87.5%) |
|
| |
| Clinical outcome † | |
| Recovery | 72/72 (100%) |